Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billionWSJ • 01/09/26
Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To CircleSeeking Alpha • 01/09/26
Merck in Talks to Buy Revolution Medicines Per Financial Times ReportZacks Investment Research • 01/09/26
Revolution Medicines Announces FDA Breakthrough Therapy Designation for ZoldonrasibGlobeNewsWire • 01/08/26
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
Revolution Medicines (RVMD) Up 27.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/25
Revolution Medicines, Inc. (RVMD) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/18/25
Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference TranscriptSeeking Alpha • 11/11/25
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales NilZacks Investment Research • 11/06/25
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressGlobeNewsWire • 11/05/25
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025GlobeNewsWire • 10/29/25
Revolution Medicines' RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic CancerGlobeNewsWire • 10/27/25
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C InhibitorGlobeNewsWire • 10/22/25
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly.Investors Business Daily • 10/17/25
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot ProgramGlobeNewsWire • 10/17/25
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development OfficerGlobeNewsWire • 09/29/25